Lv1
70 积分 2022-11-18 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7小时前
待确认
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC)
7个月前
已完结
Augmenting the synergies of chemotherapy and immunotherapy through drug delivery
9个月前
已完结
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial
9个月前
已完结
Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models
10个月前
已完结
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
1年前
已完结
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
1年前
已完结
Randomized Trial of Surgery Versus Radiotherapy in Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer After a Response to Induction Chemotherapy: EORTC 08941
1年前
已完结
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
1年前
已完结
Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
1年前
已完结
皖公网安备34019202002308
